Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poractant alfa - Chiesi/Karolinska Institute

Drug Profile

Poractant alfa - Chiesi/Karolinska Institute

Alternative Names: Curasurf; Curosurf

Latest Information Update: 22 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi; Karolinska Institute
  • Developer Chiesi; Dey Laboratories; University College Dublin
  • Class Phospholipids; Pulmonary surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neonatal respiratory distress syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neonatal respiratory distress syndrome
  • Phase III Respiratory distress syndrome

Most Recent Events

  • 16 Mar 2017 Phase-II clinical trials in Neonatal respiratory distress syndrome in Hungary (Inhalation) (EudraCT2016-004547-36)
  • 17 May 2016 Chiesi plans a phase III trial for Neonatal respiratory distress syndrome in Italy (NCT02772081)
  • 25 Feb 2015 Adverse events data from a clinical trial in Neonatal respiratory distress syndrome released by Chiesi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top